度拉糖肽治疗2型糖尿病的临床研究进展

Research progress on clinical research of dulaglutide in treatment of type 2 diabetes

目前,我国老年糖尿病患者的发病人数越来越多。GLP-1受体激动剂是一类新型作用靶点的降糖药物。新型长效GLP-1受体激动剂度拉糖肽具有改善血糖水平、降低患者体质量、每周注射1次的临床应用特点,同时该药物也具有胃肠道不适等相关的不良反应。对度拉糖肽在临床研究中的应用现状进行综述,供临床医生参考。

At present,the number of older patients with diabetes is increasing in China.GLP-1 receptor agonist is a new kind of antihyperglycemic medication.The new long-acting GLP-1 receptor agonist,dulaglutide,has been shown to control the blood glucose level,reduce the bodyweight of patients,and has been injected once a week in clinical practice.Meanwhile,the drug has also been associated with gastrointestinal discomfort and other adverse reactions.The current situation of the application of dulaglutide in clinic is reviewed in this paper,and provide reference for clinicians.